Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients

Ikhwan Rinaldi, Riki Nova, Reni Widyastuti, Rizky Priambodo, Instiaty Instiaty, Melva Louisa

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Imatinib is the first-line drug used for the treatment of chronic myeloid leukemia (CML) patients due to high molecular response and overall survival rate. However, some patients develop resistance to imatinib even after attaining a response. Mutation in ABCB1 efflux transporters is one of the known mechanisms of resistance to imatinib in chronic myeloid leukemia patients. This study was aimed to investigate the association of ABCB1 C1236T polymorphism in Indonesian chronic myeloid patients with molecular response to imatinib treatment. METHODS: We analyzed 120 samples from chronic myeloid leukemia patients in the chronic phase, who had been on imatinib treatment for at least 12 months. We analyzed the C1236T variant of the ABCB1 gene using PCR, followed by direct sequencing, and associate them with the achievement of major molecular response (MMR). RESULTS: The major molecular response was achieved in 28% of patients. The frequencies of the SNPs were CC (40%), CT (46%), and TT (14%). Our result showed that there was a lack of association between polymorphism of ABCB1 C1236T and imatinib response in Indonesian patients, with OR = 0.646 (95% CI: 0.283, 1.471; p>0.05). CONCLUSION: There was no association between ABCB1 C1236T variants with the major molecular response in Indonesian chronic myeloid leukemia patients receiving imatinib treatment.

Original languageEnglish
Pages (from-to)3331-3334
Number of pages4
JournalAsian Pacific journal of cancer prevention : APJCP
Volume20
Issue number11
DOIs
Publication statusPublished - 1 Nov 2019

Keywords

  • ABCB1
  • C1236T
  • Chronic myeloid leukemia
  • imatinib

Fingerprint Dive into the research topics of 'Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients'. Together they form a unique fingerprint.

  • Cite this